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ABSTRACT 
One of the latest trends is search for the new anti-psychotic drugs among coumarin 
derivatives with piperazine moiety. Their therapeutic potential can be hampered by poor 
physico-chemical parameters as low brain penetration or limited transport in the body fluid. 
Herein, we predicted the drug likeness of six coumarins with high affinity towards 5-HT1A and 5-
HT2A receptors. Subsequent experimental determination of their binding constants to human 
serum albumin (HSA) revealed the binding with a moderate strength (logK = 4.8 – 5.8) at the 
Sudlow’s site 1, which represents a possibility of temporary storage of tested coumarins on HSA. 
Computational mapping of the binding of coumarins - HSA complexes showed that the coumarin 
rings of all tested compounds were similarly located within the hydrophobic binding pocket of 
HSA, while the rest of molecules (composed with alkyl chains, piperazine and benzene rings) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 2 
decided about the difference in binding modes by the hydrogen bonding interactions. The proton 
dissociation constants (pKa) of the compounds were also determined by UV–vis 
spectrophotometric titrations to obtain the distribution of the species in the different protonation 
states at physiological pH of 7.4. A good agreement of the computationally-determined free 
enthalpy values of the ligand – HSA complexes with the values determined by experimental 
fluorescence quenching data could be a promising prospect for proposed theoretical strategy. 
Keywords: 5-hydroxycoumarins; drug likeness parameters; human serum albumin binding; 
fluorometry; molecular simulations; proton dissociation constants. 
1. Introduction 
The clinical potential of drugs is greatly affected by the nature of their interactions with 
circulating plasma proteins, such as human serum albumin (HSA), 1-acid glycoprotein, 
lipoproteins and -, -, -globulins (Bailey and Briggs, 2004; Bertucci and Domenici, 2002; 
Peters, 1996). Plasma protein binding can impact on the free concentration of drug in the 
circulation, the distribution around the body and the duration of drug action. It is generally 
accepted that the bound or the unbound drug molecules in blood plasma are in equilibrium, but 
only the unbound quantity of drug is pharmacologically active and able to pass through cell 
membranes (Flarakos et al., 2005). Thus, it is important to determine the fraction of unbound 
drugs at various stages of drug development, and during ADMET (absorption, distribution, 
metabolism, elimination and toxicity) parameters studies (Hogson, 2001). There is also a strong 
correspondence between interactions of drug candidate with plasma proteins and its pathways 
inside the human body, therefore computational evaluation of protein-drug energies can help in 
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the characterization of problems generated by protein binding (Ahmed-Ouameur et al., 2006; 
Curry, 2009; Flarakos et al., 2005). 
Among the plasma proteins, HSA is the most important transporter for endogenous (fatty 
acids, hormones, bile acids, amino acids, etc.) and exogenous compounds (therapeutic drugs and 
nutrients) (Bhattacharya et al., 2000; Ghuman et al., 2005; Petitpas et al., 2003), because of its 
relatively high concentration with respect to other plasma proteins (Pérez-Ruiz et al., 2010; 
Peters, 1996). The binding modes are encoded in the secondary structure of HSA which is an -
helix single-chain protein formed by three homologous domains (I, II and III) with each domain 
divided into subdomains A and B. Although many binding sites have been reported for ligands in 
HSA, the most important sites are commonly known as Sudlow´s sites 1 and 2 which are found 
in subdomains IIA and IIIA, respectively (Sudlow et al., 1976; Varshney et al., 2010). According 
to crystallographic studies ligands such as fatty acids can bind up to seven sites in HSA including 
both Sudlow´s sites (Carter and Xo, 1994). Site 1 is a large, flexible and multi-chamber cavity 
within the core of subdomain IIA that comprises all six helices of the subdomain and additional 
residues from subdomains IB, IIB and IIIA (Ryan et al., 2011). Site 2 in subdomain IIIA is 
smaller than site 1, and is a largely apolar cavity with well-defined polar features. This site 
appears to be less flexible, since ligand binding to this site often shows stereoselectivity, and 
binding is strongly affected by small structural modifications of the ligand (Ghuman et al., 
2005). Most of compounds used in human therapy bind to these two sites with affinities 
constants (K) of 10
4
 – 106 M-1 (Kratochwil et al., 2002). The ligand interaction with HSA can be 
probed by changes of fluorescence emission which is due to the presence of the single 
tryptophan residue (Trp-214) located in the subdomain IIA of site 1 (Il'ichev et al., 2002; Petitpas 
et al., 2001). 
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In recent years, various research groups have been involved in the examinations of 
conformational changes of HSA, joined with the interaction between protein and biologically 
active natural and synthetic compounds such as coumarin and its analogues (Dömötör et al., 
2014; Garg et al., 2013; Gokara et al., 2010; Yeggoni et al., 2014). The potency of coumarins 
may be modified by the number of small substituents, such as the hydroxy, alkoxy or carbonyl 
groups in various positions of coumarin moiety (Abdelhafez et al., 2010; Drzewiecka et al., 
2013; Hassan et al., 2016; Paul et al., 2013; Sarkanj et al., 2013; Tsay et al., 2013). One of the 
latest trends is search for the new anti-psychotic drugs among coumarin derivatives, and their 
affinities to serotoninergic receptors 5-HT1A and 5-HT2A were defined (Chen et al., 2014; Chen et 
al., 2013). Several studies have shown that activation of 5-HT1A receptor increases dopamine 
release in the frontal cortex, which may improve negative symptoms and cognitive deficits in 
schizophrenia (Lameh et al., 2007). Thus, coumarins are a potential resource of compounds for 
the prevention and therapy of selected central nervous system (CNS) diseases (e.g. anxiety, 
depression, schizophrenia, Alzheimer´s and Parkinson´s disease) (Skalicka-Wozniak et al., 
2016). 
In this study we selected six compounds synthesized in our research group which belong to 5-
hydroxycoumarin family connected with the N-arylpiperazine substituent via propyloxy or 
butyloxy linkers. These compounds revealed in in vitro assays very high affinities to 5-HT1A 
(IC50 within range 0.3 – 1.0 nM) and high affinities to 5-HT2A (IC50 within range 9.0 – 184.0 nM) 
receptors (Ostrowska et al., 2017). As the next step in the pipeline of drug discovery are in vivo 
tests, we calculated the theoretical values of the physico-chemical and biopharmaceutical 
parameters which describe the absorption, distribution, metabolism, elimination and toxicity 
(ADMET) in the human body to select the best candidates to these examinations. All compounds 
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were predicted to bind to blood plasma proteins. Then, we used the combination of experimental 
and computational techniques to understand and characterize the interactions of tested 
compounds with a major carrier protein HSA using fluorescence spectroscopic technique, 
molecular docking and molecular dynamics (MD) simulations. 
 
2. Theoretical methodology 
2.1. Theoretical structures of protein and ligands 
We tested six compounds: 6-acetyl-4,7-dimethyl-5-[3-(4-(2,3-dichlorophenyl)piperazin-
1-yl)propoxy]coumarin (1), 6-acetyl-4,7-dimethyl-5-[3-(4-(2-fluorophenyl)piperazin-1-
yl)propoxy]coumarin (2), 6-acetyl-4,7-dimethyl-5-[3-(4-(3-methoxyphenyl)piperazin-1-
yl)propoxy]coumarin (3), 6-acetyl-4,7-dimethyl-5-[3-(4-(2-cyanophenyl)piperazin-1-
yl)propoxy]coumarin (4), 6-acetyl-4,7-dimethyl-5-[4-(4-(2-fluorophenyl)piperazin-1-
yl)butoxy]coumarin (5) and 4,7-dimethyl-5-[4-(4-(3-methoxyphenyl)piperazin-1-
yl)butoxy]coumarin (6) (Fig. 1) which showed the highest affinity towards 5-HT1A and 5-HT2A 
receptors. They belong to two groups of coumarin derivatives, which differ in the length of the 
linker between the coumarin and the piperidine rings: compounds 1 – 4 have propylene and 
compounds 5 – 6 have butylene chains. Coumarin derivatives are poorly soluble in water, and 
prior to biological tests they were transformed into hydrochlorides to increase solubility. For 
consistency sake we analyzed the cations of 1 – 6 in the theoretical studies. Three-dimensional 
structures of ligands were prepared using Discovery Studio 4.5 visual interface BIOVIA (Biovia 
Software Inc., 2015). Geometries of all compounds were optimized using the density functional 
theory (DFT) with the B3LYP/6-311G (d,p) hybrid functional, as implemented in Gaussian 09 
(Frish et al., 2009). ESP-atomic partial charges on all atoms were computed using the Breneman 
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model reproducing the molecular electrostatic potential (Breneman and Wiberg, 1990). The 
structures were then exported into the 3D SDF format and used as input in ADMET Predictor
TM
 
version 8.0 (Simulations Plus Inc.) software to calculate the values of molecular descriptors by 
the mathematical models. The crystal structure of HSA (PDB ID: 2BXD) was obtained from the 
RCSB Protein Data Bank. The PDB file presents a co-crystal with a warfarin ligand in the active 
site. Ligand, water molecules and inorganic ions were removed prior to the calculations and 
hydrogen atoms were added to reflect the physiological pH. 
2.2. Prediction of drug likeness descriptors and toxicity 
The molecular descriptor values of compounds 1 – 6 were used as inputs to mathematical 
models implemented in ADMET Predictor
TM
 version 8.0 in order to generate estimates for each 
of the ADMET property. In this study we checked Lipinski’s rule of five and then we calculated 
the following descriptors: the topological polar surface area (TPSA), distribution coefficient 
logD (at pH = 7.4), the volume of distribution (Vd), the solubility (Sw), the proton dissociation 
constants (pKa), Madin-Darby Canine Kidney cells apparent permeability (MDCK), the effective 
permeability (Peff), the blood-brain BBB filter, the blood-brain barrier (BBB) partition coefficient 
logCbrain/Cblood (logBB), percentage of unbound drug to proteins within blood plasma (%Unbnd) 
and blood-to-plasma concentration ratio (RBP = Cwhole-blood/Cplasma). Toxicity profile was 
characterized by Maximum Recommended Therapeutic Dose (MRTD), cardiac toxicity by 
affinity towards hERG-encoded potassium channels, and the hepatotoxicity (described by the 
level of alkaline phosphatase (AlkPhos), -glutamyl transferase (GGT), serum glutamate 
oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) and lactate 
dehydrogenase (LDH)). 
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2.3. HSA-ligand docking study 
 Docking was performed using AutoDock 4.2.3 software (Morris et al., 2009), and the 
Lamarckian Genetic Algorithm (LGA) (Morris et al., 1998), since it was found to be the best 
performing docking method in terms of its ability to find the lowest energy (Morris et al., 1996; 
Morris et al., 2009). The protein input files were prepared for docking by adding Gasteiger 
charges on atoms. Based on the site-specific markers used in our experiment, we have obtained 
that coumarins binds specifically to the site 1. Moreover, many studies proposed Sudlow´s site 1 
as the binding region for warfarin and bulky heterocyclic compounds (Ghuman et al., 2005). In 
all dockings, a grid map with 50  50  50 Å points along the x, y and z axes, and a grid-point 
spacing of 0.375 Å was applied and the maps were centered on C of Trp-214. We used the 
following GA docking parameters: 30, number of individual in the population: 150, maximum 
number of energy evaluations: 250 000 and maximum number of generations: 27 000. During 
docking, a maximum number of 30 conformers was considered, and the root mean square (RMS) 
cluster tolerance was set to 2 Å. The lowest energy conformations were used as the starting 
points in the molecular dynamics (MD) simulation. 
2.4. Interaction with HSA: molecular dynamics study 
 MD simulations of the ligand-protein complexes were performed to further investigate 
ligands binding, and the effect of their structures on the intermolecular interactions. We used the 
CHARMm force field (Brooks et al., 1983) implemented in the module of Discovery Studio 4.5. 
The HSA complexes were surrounded by a cubic box of water molecules (TIP3P model 
(Jorgensen et al., 1983)) extending up to a distance of 12 Å from any solute atom. Additional Na 
and Cl ions were added randomly to each complex at a concentration of 0.15 M, close to 
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physiological conditions (Aqvist, 1990) using the Solvation module of Discovery Studio 4.5. All 
energy minimization and molecular dynamics simulations were performed using the Particle 
Mesh Ewald (PME) method (Essmann et al., 1995) for the correct treatment of electrostatic 
interactions (Sagui and Darden, 1999) and periodic boundary conditions. All initial 
configurations were optimized by a series of energy minimizations: first only keeping the solvent 
fixed, second, keeping the protein and coumarin derivative fixed, and finally removing all 
constraints. The restrains were weak with force constant of 2 kcal/(molÅ2). Next, energy 
minimization was performed using the steepest descent algorithm of 1000 steps, followed by the 
conjugate gradient algorithm for 1000 steps to reduce unfavorable intermolecular steric contact 
(until the RMS gradient of the structure was below 0.01 kcal/(molÅ)). The MD protocol 
contained a heating step performed for 50 ps with a time step of 1 fs when the system was heated 
from 50 to 300 K. Prior to the production stage, the system was equilibrated by allowing it to 
evolve spontaneously until the average temperature and the structure remained stable and the 
total energy converged. The total number of steps to perform the dynamic simulation was 200 ps. 
The periodic boundary condition was used and the motion equations were integrated by applying 
the Leapfrog Verlet algorithm (Verlet, 1967) with a time step of 2 fs. To allow one to keep bonds 
involving the H atoms at their equilibrium length, the SHAKE algorithm (Ryckaert et al., 1977) 
was used. The equilibrated system was taken as the starting structure for 5 ns production runs in 
the NPT ensemble, at a temperature of 300 K maintained using a Berendsen thermostat 
(Berendsen et al., 1984). The coordinates were recorded every 10 ps. Trajectory structures for 
analysis were saved at 1 ps. 
2.5. Interaction with HSA: binding free enthalpy calculations 
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The free enthalpy analysis was performed using the MD implementation of the MM-
PBSA approach (Kollman et al., 2000), based on the MD trajectories obtained using explicit 
solvent molecules. The binding free enthalpy (Gbind) of coumarin derivatives to HSA was 
calculated using the following equation: 
           Gbind = GHSA-ligand – GHSA – Gligand                                                  (1)  
where GHSA-ligand – free enthalpy of complex, GHSA – free enthalpy of HSA and Gligand – free 
enthalpy coumarin derivative. 
 We used 500 snapshots of the solute sampled regularly from the last nanoseconds of the 
MD trajectories, with the water and counter ions removed. This method combines the enthalpy or 
molecular mechanics energies (EMM) that represent the internal energies along with van der 
Waals (EvdW) and electrostatic interactions (Eelec), with the solvation free enthalpy (Gsolv) 
calculated by the finite difference Poisson-Boltzmann (PB) model for polar solvation (GPB or 
Gpolar) and the non-polar contribution (Gnon-polar) as a function of solvent-accessible surface area 
(SASA). All terms were computed with the Discovery Studio 4.5 program.  
 Binding free enthalpy was calculated based on the average structures obtained from the 
last 3 ns of MD trajectories. The components of each complex were minimized using the 
conjugate gradient method for 10 000 steps after 100 steps of the steepest descents algorithm and 
a dielectric constant of 4 for the electrostatic interactions until the RMS gradient of the structure 
was less than 0.001 kcal/(molÅ). 
3. Experimental section  
3.1. Preparation of stock solutions 
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HSA (as lyophilized powder with fatty acids), NaH2PO4, Na2HPO4, KOH, HCl and NaCl 
were obtained from Sigma-Aldrich in puriss quality. Doubly distilled Milli-Q water was used for 
sample preparations. HSA solution was freshly prepared before the experiments and its 
concentration was estimated from its UV absorption: 280 nm(HSA) = 36850 M
−1
·cm
−1
 (Chasteen 
et al., 1986). Stock solutions of coumarin derivatives were prepared in water from their 
hydrochloride salts (pH ~ 4) at 100 µM concentration. 
3.2. pH-dependent UV-visible spectrophotometric and spectrofluorometric studies of the 
ligands 
The pH-dependent measurements for the determination of the proton dissociation 
constants (pKa) of the compounds 1 – 6 were carried out at 25.0 ± 0.1 °C in aqueous phase at a 
constant ionic strength of 0.10 M (KCl). The titrations were performed with a carbonate-free 
KOH solution (0.10 M) and its concentration was determined by pH-potentiometric titrations. 
pH-Dependent titrations were performed in the pH range 2.0 – 11.5. The initial volume of the 
samples was 10.0 mL. Samples were deoxygenated by bubbling purified argon through them for 
ca. 10 min prior the measurements. 
The proton dissociation constants and the spectra of the individual species in the various 
protonation states were calculated with the computer program PSEQUAD (Zékány et al., 1985). 
The calculations were always made from the experimental titration data measured in the absence 
of any precipitate in the solution. A Hewlett Packard 8452A diode array spectrophotometer was 
used to record the UV-visible (UV-vis) spectra in the interval 200 – 800 nm. The path length was 
4 cm. The spectrophotometric titrations were performed on samples containing 2.0 µM tested 
compounds. 
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The fluorescence spectra of the compounds were recorded at pH 7.4 on a Hitachi-4500 
spectrofluorometer with the appropriate excitation wavelength and emission wavelength ranges. 
The emission spectra were recorded in 1 cm quartz cell at 25.0 ± 0.1 °C using 5 nm/5 nm slit 
widths. The samples contained 2.5 – 10 µM tested compounds. Three-dimensional spectra were 
recorded in the 250 – 500 nm excitation and 260 – 600 nm emission wavelength regions at 
various pH values. 
3.3. Interaction with HSA: Spectrofluorometric studies 
All samples were prepared in 20 mM phosphate buffer (pH 7.4) and 0.1 M KCl. Samples 
contained 1 µM HSA and various HSA-to-ligand ratios (from 1:0 to 1:10) were used. Spectra 
were recorded after 60 min incubations. The excitation wavelength was 295 nm; the emission 
intensities were read in the range of 310 – 600 nm with 5 nm/5 nm slit widths. The conditional 
binding constants (logK) were calculated with the computer program PSEQUAD as described in 
the Supplementary data. 
Corrections for self-absorbance and inner filter effect were necessary in the quenching 
experiments because fluorescence light was significantly absorbed by the coumarin derivatives. 
The corrections were carried out according to the following equation: 
                                               Fcorrected = Fmeasured · 10
(A
(EX)
 + A
(EM)
) / 2
                                             (2) 
where Fcorrected and Fmeasured are the corrected and measured fluorescence intensities, and A(EX) 
and A(EM) are the absorbance values at the excitation and emission wavelengths of the samples, 
respectively. 
4. Results and discussion 
4.1. In silico drug likeness and toxicity assessments  
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 Seven principal descriptors and sixteen predicted ADMET properties were calculated for 
six analyzed coumarin derivatives. Principal descriptors (Lipinskis rule of five and the 
topological polar surface area (TPSA) and pKa values) are given in Table 1. TPSA values of all 
compounds were found to be between 55.15 and 86.78 Å and lay within the range for a drug with 
the passive molecular transport through membranes. The values below 90 Å create favorable 
conditions for the penetration BBB which is important for the ligands interacting with brain 
receptors. The logP values were within the range 3.83 – 4.81 for the majority of compounds what 
is in an agreement with the values for well absorbed compounds. For two coumarin derivatives, 
1 and 6, the logP values were predicted to be above 5 indicating even higher lipophilicity. We 
also examined pH-dependent logD values, which give estimate of the lipophilicity of a drug at 
the pH of blood plasma. For all compounds the logD values are predicted to be in the 3.77 – 5.01 
range, exceeding the traditionally cutoff value of 3.5. The lower lipophilicity value of 4 suggests 
that it is mostly in the free form and can be distributed to blood cells whereas the higher 
lipophilicity values of 1 – 3 and 5 – 6 indicates higher probability of binding to plasma proteins 
(Wils et al., 1994) (Laznicek and Laznickova, 1995). In the study, also specific attention was 
given to pKa values. The predicted pKa values of all compounds fall in the range of 6.60 - 7.45 
(see Table 1) and can be attributed to the deprotonation of one of the piperazine nitrogen’s +NH 
(Fig. S1). The change from butylene to propylene linker slightly decreases the pKa values. The 
molecular weights (MWt) of all investigated systems are in the range defined for orally available 
compounds and only compound 1 has the MWt of more than 500 g/mol, since two chlorine atoms 
at positions 2 and 3 of the benzene ring increase its MWt to 503.43 g/mol. The number of atoms 
which can be engaged in the intermolecular hydrogen bonds and the number of rotatable bonds 
are also within the usually-acceptable ranges. 
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The predicted drug likeness parameters (volume of distribution (Vd), water solubility 
(Sw), effective permeability (Peff), apparent permeability (MDCK), BBB_filter, blood-brain 
barrier partition coefficient (logBB), percentage of unbound drug to blood plasma proteins 
(%Unbnd), blood-to-plasma concentration ratio (RBP) are shown in Table 2. The volume Vd is 
the primarily pharmacokinetic parameter which can help in defining the dose required to give a 
certain plasma concentration. Vd values of six tested compounds are in the range 3.533 – 6.205 
L/kg, and they are not distributed in all tissues in the body. Compounds 4 and 6 which have 
value below 3.7 L/kg are predicted to be confined to the blood plasma, whereas compounds 1, 2, 
3 and 5 have values higher than 3.7 L/kg, what suggests that they are distributed in whole blood. 
The aqueous solubility (Sw) significantly affects absorption and distribution characteristics of a 
compound. The Sw values for all compounds are predicted to be in the 0.00037 – 0.014 mg/mL 
range and only one system is predicted to have acceptable solubility (4,7-dimethyl-5-[4-(4-(3-
methoxyphenyl)piperazin-1-yl)butoxy]coumarin (6) – Sw = 0.014 mg/mL). Human jejunal 
permeability (Peff) reflects the passive transport velocity in cm/s across the epithelial barrier in 
the human jejunum – the region of the intestinal tract with the largest surface area. The predicted 
Peff values are in the region 3.581 – 5.137 cm/s10
4
 what show their high jejunal permeability. 
Madin-Darby Canine Kidney (MDCK) values obtained in the range 624 – 1224 cm/s107 
showing good apparent membrane permeability. 
The next molecular descriptors (BBB_filter and log BB) determine the likelihood of 
crossing the BBB. These parameters are crucial in drug design of CNS-active compounds. Both 
parameters (see Table 2) for six coumarins studied are characteristic for compounds which cross 
the BBB. The highest concentration in brain is predicted for compound 5 with (2-
fluorophenyl)piperazinyl moiety connected via butylene linker. Another important property of a 
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potential drug is its ability to bind to plasma proteins, which is in most cases considered as 
undesirable. On the other hand binding to HSA can increase the drug’s biological half-life. Two 
parameters characterize these properties: the percent of drug unbound to protein within blood 
plasma (%Unbnd) and the concentration of the drug in whole blood compared to plasma (RBP). 
For the majority of analyzed coumarins the values of %Unbnd are in the region 0 – 1.563%, and 
the values of RBP in the region 0.62 – 1.38 (see Table 2), what suggests that all compounds fall 
in the region of high plasma protein binding. 
The predicted toxicity parameters for coumarins are shown in Table 3. MRTD is a 
qualitative assessment of the maximum recommended therapeutic dose administrated with the 
threshold for dose-related side effects of 3.16 (mg/kg-bw/day). All tested coumarins have MRTD 
values below 3.16 (mg/kg-bw/day) indicating potential side effects. The hepatotoxicity models, 
however, predicts all coumarins as “non-toxic”. On the other hand six coumarins are also 
predicted as having potential cardiotoxicity and hERG_pIC50 values are in the range between 
6.20 and 7.07, exceeding the cutoff value 5.5. It means that these compounds can potentially 
block hERG channels in the heart cells leading to cardiac problems. 
Because the increase of toxicity is forced by the increasing the therapeutic dose, we are 
taking into account high values of plasma binding of tested coumarins. Our further studies were 
devoted to the analysis of molecular mechanism of 5-hydroxycoumarin derivatives binding to 
HSA by experimental measurements and molecular modeling. Analyses of albumin-coumarin 
interactions can be useful for providing safer and efficient therapy. 
4.2. Spectrofluorometric studies of interaction with HSA 
The interaction of compounds 1 – 6 with human serum albumin (HSA) has been 
investigated by fluorescence quenching spectroscopy. HSA is the most abundant plasma protein 
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(~630 μM) and serves as a transport vehicle for a wide variety of endogenous compounds and 
pharmaceuticals. The intrinsic fluorescence of HSA is due to aromatic amino acid residues such 
as tryptophan, tyrosine and phenylalanine (Fanali et al., 2012; Peters, 1996). This protein 
contains a single tryptophan (Trp-214) residue that is the dominant source of its intrinsic 
fluorescence, since Trp has much higher quantum yield compared to that of the other two amino 
acids. Trp-214 is located near to site 1, hydrophobic binding pocket in subdomain IIA. Upon 
excitation at 295 nm, HSA emits strong fluorescence at 340 nm which can be attenuated by a 
binding event at, or close to, the Trp-214 due to its high sensitivity to changes in its (local) 
environment (Fanali et al., 2012; Peters, 1996; Sudlow et al., 1976). Therefore, fluorescence Trp-
214 quenching is a simple and indispensable method for monitoring binding at site 1. 
Time-dependence measurements on the HSA-compound interaction revealed that the 
reaction is relatively fast (completed within 20 min), and to ensure the equilibrium state 1 h 
incubation time was used for the quenching experiments. The self-absorption of the samples is 
significant at the wavelength range of the quenching measurements; thus a correction equation 
was applied to minimize this effect. Representative fluorescence emission spectra recorded for 
the 6 ‒ HSA system at various ratios are shown in Fig. 2, and for 1 ‒ HSA system in Fig. S2. As 
the studied compounds possess intrinsic fluorescence, their own emission bands are partly 
overlapped by that of HSA. The overlapping of the spectra of HSA and 3 concerns a too wide 
wavelength range that hindered the determination of the quenching constant. In the other cases a 
wavelength range, in which no significant contribution of the compound’s emission to the 
intensity is seen, could be chosen for the calculations (e.g. 310 – 360 nm for 6, see Figs. 2b and 
2c). The conditional stability constants (logK) were computed with the computer program 
PSEQUAD, and are collected in Table 4. It is worth mentioning that the intensities do not tend to 
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zero intensities at the (EM)max value of HSA (Fig. 3); and this phenomenon was included in the 
calculations (see the Supplementary data for the calculations). A possible explanation of this 
effect can be the partial quenching of Trp-214 emission instead of complete quenching; 
moreover HSA contains other less emitting residues like Tyr whose emission is not affected by 
an interaction on site 1. 
The changes of the emission intensity of the compounds upon binding to HSA were also 
analyzed. Fig. 3 shows the intensity of 6 at 452 nm in the absence and in the presence of the 
protein and only a minor difference can be observed. Similar findings for the other compounds 
also confirm that the emission intensity of them was insensitive to binding to HSA in our study. 
Thus no binding constants could be calculated from the side of the compounds, only via the Trp-
214 quenching. Representative three-dimensional fluorescence spectra of 3, HSA and the 3 -
HSA system at pH 7.4 (Fig. 4) clearly show that the peak belonging to the HSA is decreased 
upon binding, while the peak of the compound shows a minor alteration. 
In order to compare the quenching ability of the compounds I/I0 values at the emission 
maximum (338 nm) are plotted against the HSA-to-ligand ratios (Fig. 5). The fluorescence 
intensity was slightly increased in the case of 3 due to the overlapping with the emission band of 
the compound itself (see above). A clear trend is seen here as well as the calculated logK values 
(Table 4) show the order of the binding strength at site 1 on HSA: 6, 1 > 4 > 2 > 5. (Notably, 
data obtained for 5 was not adequate for the accurate calculations due to the small changes 
detected.) It could be concluded based on the fluorescence quenching study with HSA that the 
compounds showed a significant binding on site 1. The determined binding strength (logK = 4.8 
– 5.8) is weaker than that of several reduced Schiff base coumarin derivatives studied in our 
former work (Dömötör et al., 2014). Received dissociation constants (KD ~ 1.6 – 16 µM) were 
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higher than those obtained before (KD ~ 0.03 – 2.09 µM), however recently tested molecules are 
smaller and contain a phenolate moiety that plays important role in the binding via electrostatic 
interactions. 
4.3. Site 1 with starting conformations of 5-hydroxycoumarins by molecular docking 
 The most favorable six conformations of 1 – 6 with the lowest docking energy were 
found in 30 independent runs. The free energies estimated by intermolecular energy (including 
van der Waals energy, hydrogen bonding energy and electrostatic energy) were as follows -5.47 
kcal/mol (1), -5.06 kcal/mol (2), -3.34 kcal/mol (3), -5.19 kcal/mol (4), -4.54 kcal/mol (5) and -
5.69 kcal/mol (6). The conformations corresponding to the lowest energies were selected for MD 
simulations. 
The 3D views of site 1 in HSA are shown in Fig. 6. In Fig. 6a there is a hydrophilic 
region at the entrance of the pocket (formed by Tyr-150, Lys-195, Lys-199, Arg-218, Leu-219, 
Arg-222, and Glu-292), and a hydrophobic region at the bottom (formed by Trp-214, Arg-218, 
Leu-219, Leu-234, Leu-238, His-242, Arg-257, Leu-260, Ala-261, Ile-264, Ile-290, and Ala-
291). The predicted location of studied coumarin derivatives in HSA pocket is similar (see Fig. 
6b), and their interactions are mainly hydrophobic in nature. The schematic presentation of 
interactions between coumarin derivatives and HSA is shown in Fig. S3 in Supplementary data. 
In the best binding poses coumarin derivatives are surrounded by hydrophobic residues and there 
is a considerable number of hydrogen bonds and electrostatic interactions due to the presence of 
several hydrophilic amino acids such as Tyr-150, Ser-192, Lys-195, Arg-218, Glu-153, Arg-222, 
His-242, Arg-257, His-288, Ala-291 and Glu-292 in the vicinity of the ligand. The formation of 
unfavorable bonds was noticed for all compounds between the proton at the piperazine nitrogen 
and Lys-199, and for compounds 3, 4, 5 additionally with Arg-222. 
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4.4. Binding free enthalpy and interactions of 5-hydroxycoumarin derivatives 1 – 6 with HSA  
 Finally, the structures of HSA complexes with 1 – 6 were built using MD methodology 
described in Section 2.4. The resulted RMSD values between the ligand starting and average 
structures were low in all cases. The theoretical binding free enthalpy values were calculated and 
are shown in Table 5 together with the experimental values obtained using Gibbs´ isotherm and 
logK values (Gexp = -2.303·R·T·logK). The computationally calculated binding free enthalpies 
and the experimentally obtained values are similar with the maximum difference of 1.23 
kcal/mol. The resulting differences may be due to that, the X-ray structure of the protein from 
crystals even after MD simulation differs from that of aqueous conditions. Compounds 1 – 6 
bind to site 1 in different way and with different affinities. The binding affinities decrease in the 
sequence: 6 > 1 > 4 > 2 > 5 > 3 (-8.26 kcal/mol > -7.04 kcal/mol > -5.75 kcal/mol > -5.31 
kcal/mol > -5.75 kcal/mol > -4.09 kcal/mol > -3.03 kcal/mol). The structures of HSA – ligand 
complexes are shown in Fig. 7 for 1 – 4 and in Fig. 8 for 5 and 6. Additionally, the location of 
ligands in respect to Trp-214 was shown in Fig. S4 in Supplementary data. 
The coumarin rings of all tested compounds were similarly located within the 
hydrophobic binding pocket of HSA, while the rest of molecules (composed with alkyl chains, 
piperazine and benzene rings) decided about the difference in binding modes. Compounds 1, 3 
and 4 with propylene linker are predicted to be accommodated in the HSA pocket in folded 
conformations, but compound 2 adopted an extended conformation. The coumarin ring of 1 is 
rotated by 180
o
 when compared with coumarin rings of 2, 3 and 4. Compound 1 is surrounded by 
Tyr-150, Ala-291, His-242 and Glu-292 of HSA forming hydrogen bonds with the ligand, and 
Lys-195 and Arg-222 creating electrostatic interactions with the 2,3-dichlorophenyl moiety. It 
can be observed that the methyl group at 7-position makes π-interactions with the indole ring of 
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Trp-214 (the length of 2.27 Å, Fig. S4). The conformations and locations within the cavity of 3 
and 4 are almost the same, but nitrile group of 4 formed a very strong hydrogen bond with Lys-
199, which can be responsible for its higher affinity than 3. 
Compounds 5 and 6 with butylene linker are clustered in the center of site 1 of HSA, and 
in Fig. 8 it can be seen that their conformations are rather different. Coumarin ring in 6 adopts 
the similar orientation like this of 1. Apart of typical interactions, folded conformation of 6 
allowed for favorable interactions of the 3-methoxyphenyl moiety with Pro-447 and Asp-451 and 
the water molecule. It is worth noticing that the Trp-214 residue of HSA is near to 6, forming the 
hydrophobic interaction similar to that of 1 (Fig. S4). The highest affinity of 6 can be attributed 
to the folded conformation and may be facilitated by the lack of the acetyl substituent and 
butylene chain. This hypothesis can be supported by lower affinity of 3, which is the derivative 
with both the acetyl group and propylene chain. The 5 – HSA complex showed a similarly 
extended conformation as the 2 – HSA complex with the 2-fluorophenyl substituent. 
Fluorophenyl substituents interacted with Glu-292 and Glu-153 in 5, and with Ser-192, Glu-292 
and Lys-195 in 2. On the basis of theoretical results it can be concluded that all structural 
features (the substituents, length of alkyl chain) play important role in HSA binding. Compounds 
1 and 6 with the highest affinity have almost identical location in Sudlow’s site 1 and are in 
proximity of Trp-214. 
4.5. Proton dissociation processes and fluorescence properties of the compounds 
The selected compounds have insufficient water solubility, therefore their proton dissociation 
processes were studied in pure aqueous solution at fairly low concentration (2 µM) by UV-vis 
spectrophotometry. However, the presence of the coumarin moiety in the compounds results in 
relatively strong absorption in the UV region. In order to obtain adequately high absorbance 
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values 4 cm path length had to be applied. Based on the UV-vis spectra recorded at various pH 
values one deprotonation process was observed in all cases, and pKa values obtained by the 
deconvolution of the spectra are collected in Table 4. Representative UV-vis spectra are shown 
for 6 in Fig. 9a, which reveal relatively minor changes upon deprotonation. The proton 
dissociation constants can be attributed most probably to the deprotonation of one of the 
piperazine nitrogen’s, namely to the +NH ‒ CH2 moiety as was mentioned in Section 4.1 and 
showed in Fig. S1. As this moiety is located relatively far from the chromophore groups (phenyl 
and coumarin) it is reasonable that the absorption spectra are not so sensitive to the 
deprotonation. 
Figs 9b and 9c represent the decreasing absorbance values for 6 at 306 nm and concentration 
distribution curves as a function of pH calculated on the basis of the pKa value. Calculated molar 
absorbance spectra are shown for selected compounds in Fig. 10, and max and molar absorptivity 
() values for the HL+ and L forms are collected for all studied compounds in Table 4. It can be 
concluded that in all cases the HL
+
 → L process is accompanied by a minor decrease of the max 
values and diminished absorbance of the well-defined band at 286 ‒ 306 nm. The pKa values 
calculated based on the experimental data collected in aqueous solution fall in the range of 6.54 ‒ 
7.09. It can be seen that the exchange of the butylene linker between the coumarin and piperazine 
moieties to propylene linker slightly decreases the pKa values, and the presence of the chlorine 
substitutes undoubtedly increases the acidity of the compounds due to its high electron 
withdrawing effect. Interestingly the fluorine monosubstitution resulted in a small increase in the 
pKa values. Notably the experimentally obtained pKa values show a good agreement with the 
predicted ones (Table 1) in the case of ligands 1 ‒ 3, although they differ more significantly for 4 
‒ 6. 
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Based on the determined pKa values distribution at pH 7.4 was calculated (Table 4). All the 
compounds are partly protonated at this pH and 12 ‒ 33% are present in the positively charged 
HL
+
 form. The strongly lipophilic nature of the studied compounds did not allow us to determine 
the n-octanol/water partition coefficients (logP) by the traditional saturation shake flask method 
(see calculated values vide supra). Notably, the protonation of the Npiperazine‒CH2 moiety 
enhances the water solubility so much that acidic stock solutions of 100 µM concentration (pH ~ 
4) could be prepared for the measurements. 
As the studied compounds contain the coumarin moiety, their fluorescence activity is expected. 
Therefore fluorescence properties were studied and the (EM)max values are collected in Table 4. It 
was found that in spite of the close structural similarities of the compounds their fluorescence 
property was quite different depending on the nature and position of the substituents.Although 
the (EM)max values are similar (439 ‒ 445 nm), their fluorescence intensities considerably differ 
(Table 4). The compound 6 was found to be the strongest emitting compound, while fluorescence 
of 1 is almost negligible.
5. Conclusions 
Drug likeness characteristics computed for six coumarins with strong binding ability 
towards 5-HT1A and 5-HT2A receptors allowed for evaluation of their drug potency. TPSA values 
of all compounds were found within range 55.15 – 86.78 Å what means that they capable of the 
penetration of the BBB what is important for the potential ligand of brain receptors. Theoretical 
values of the percent of drug unbound to protein within blood plasma (%Unbnd) were in the 
range 0 – 1.6 % suggesting that tested coumarins are characterized by a significant plasma 
protein binding. Examinations of coumarin derivatives affinities to HSA by fluorescence 
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quenching spectroscopy revealed moderate binding of coumarins 1 – 6, suggesting a specific role 
of HSA as a carrier molecule of coumarins with piperazine moiety. The experimental data were 
in good agreement with the computationally-derived free enthalpies of binding obtained by MD 
ligand docking in Sudlow´s site 1. In-silico analysis of the interactions of coumarin derivatives 
with HSA shed more light onto the interpretation of mode of action of investigated coumarins 
which can be mainly characterized as the hydrophobic and hydrogen bonding types. 
Experimentally determined acidity constants (pKa) allowed the determination of distribution of 
ligands in the various protonated forms at pH 7.4. It showed that 12 – 33% of compounds are 
present in their positively charged HL
+
 form, in which the piperazine nitrogen is protonated. On 
the basis of received results the tested coumarins could be considered as promising compounds 
for further development steps as novel therapeutic agents. 
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Figure and Table legends 
Fig. 1. Chemical structures of the coumarin derivatives studied. 
Fig. 2. Fluorescence emission spectra of 6 ‒ HSA system (a, b), and 6 alone (c) at various 
concentrations. (cHSA = 1 µM; c6 = 0-10 µM; EX = 295 nm; t = 25 °C; pH = 7.40 (20 mM 
phosphate buffer); I = 0.1 M (KCl)). 
Fig. 3. Fluorescence emission intensities recorded for the 6 ‒ HSA system at various ratios at 
338 nm (□) and at 452 nm (■). The grey dotted line shows the independent calibration for 6. 
(cHSA = 1 M; c6 = 0-10 M; EX = 295 nm; t = 25 °C; pH = 7.40 (20 mM phosphate buffer); I = 
0.1 M (KCl)). 
Fig. 4. Three-dimensional fluorescence spectra of compound 3 (a) HSA (b) and HSA ‒ 3 (1:4.5) 
system (c) (cHSA = 1 M; c3 = 4.5 M; t = 25 °C; pH = 7.40 (20 mM phosphate buffer); I = 0.1 
M (KCl)). 
Fig. 5. Measured quenching of the Trp fluorescence emission intensity of HSA as I/I0 (%) by the 
addition of 6 (□), 3 (×); 5 (♦); 2 (∆); 1 (+); 4 (●). (cHSA = 1 M; EX = 295 nm, EM = 338 nm; t = 
25 °C; pH = 7.4 (20 mM phosphate buffer); I = 0.1 M (KCl)). 
Fig. 6. Views of coumarin derivatives in site 1 of HSA. (a) The hydrophobic and hydrophilic 
amino acid residues surrounding the ligands. Surface hydrophobicity was depicted by the shaded 
colors: brown - the hydrophobic and blue - the lipophilic regions. (b) Superposition of 
compounds: 1 (green), 2 (blue), 3 (orange), 4 (red), 5 (pink), 6 (dark blue). 
Fig. 7. Structures of the 1-HSA, 2-HSA, 3-HSA and 4-HSA complexes, and 2D view of all HSA 
residues interacting with the ligands resulting from MD simulations (residues involved in 
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hydrogen bonding marked as green and cyan circles; in hydrophobic interactions marked as pink 
circle and electrostatic interactions marked as orange circle). 
Fig. 8. Structures of the 5-HSA and 6-HSA complexes, and 2D view of all HSA residues 
interacting with the ligands resulting from MD simulation (residues involved in hydrogen 
bonding marked as green and cyan circles; in hydrophobic interactions marked as pink circle and 
electrostatic interactions marked as orange circle). 
Fig. 9. pH-dependent UV-vis spectra of 6 (a), measured (×) and fitted (solid line) absorbance 
values at 306 nm as a function of pH (b), and concentration distribution curves (c). (c = 1.98 M; 
l = 4 cm; t = 25 °C; I = 0.1 M (KCl)). 
Fig. 10. Calculated molar absorbance spectra for ligand species of 2 (black lines), 5 (grey lines) 
(a); and 4 (black lines), 1 (grey lines) (b) obtained by the deconvolution of the UV-vis spectra 
recorded at various pH values. (t = 25 °C; I = 0.1 M (KCl)). 
Table 1. The topological polar surface area (TPSA), parameters of Lipinski´s rule of five, and 
predicted proton dissociation constants (pKa) for coumarins 1 – 6. 
Table 2. Theoretical values of water solubility Sw, effective permeability Peff, apparent 
permeability MDCK, percentage of unbound drug to blood plasma proteins %Unbnd, blood-to-
plasma concentration ratio RBP, BBB filter, blood-brain barrier partition coefficient logBB for 
coumarins 1 – 6. 
Table 3. Predicted toxicity parameters for coumarins 1 – 6: maximum recommended therapeutic 
dose MRTD, level of alkaline phosphatase (AlkPhos); level of -glutamyl transferase (GGT), 
level of serum glutamate oxaloacetate transaminase (SGOT), level of serum glutamate pyruvate 
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transaminate (SGPT), level of lactate dehydrogenase (LDH); cardiotoxicity – hERG_filter and 
affinity for hERG K
+
 (hERG_pIC50). 
Table 4. Proton dissociation constants (pKa) of for coumarins 1 – 6 determined by UV-vis 
spectrophotometric titrations, distribution at pH 7.4 and max,  values of the ligand species; 
EM)max and relative fluorescence emission intensity values for the compounds at pH 7.4; 
conditional binding constants to HSA on site 1 (logK) (t = 25C). 
Table 5. Theoretical and experimental free enthalpies of binding to HSA, and theoretical average 
distance of ligand to tryptophan Trp-214 for coumarins 1 – 6. 
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Fig. 3. 
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Fig. 4. 
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Fig. 9. 
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Fig. 10. 
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Table 1. 
Compound 
TPSA 
 
MWt 
 
LogP 
 
LogD 
 
HBD 
 
HBA 
 
pKa 
expected values 
(<140Å
2
) (500 g/mol) (5) (3.5) (5) (8) 
1 62.99 503.43 5.12 5.01 0 6 6.86 
2 62.99 452.53 4.50 4.36 0 6 6.98 
3 72.22 464.57 4.30 4.21 0 7 6.79 
4 86.78 459.55 3.83 3.77 0 7 6.60 
5 62.99 466.56 4.81 4.48 0 6 7.45 
6 55.15 436.56 5.11 4.81 0 6 7.39 
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Table 2. 
Compound 
Vd Sw Peff MDCK %Unbnd RBP 
BBB 
filter 
logBB
 
expected values 
( 3.7 
L/kg) 
(0.010 
mg/mL) 
( 0.5 
cm/s·10
4
) 
( 30 
cm/s·10
7
) 
(>10%) (<1) 
(high/ 
low) 
 
1 4.622 0.001 5.137 1223.743 0.632 0.684 high 0.275 
2 4.551 0.003 4.482 706.579 1.115 0.669 high 0.215 
3 3.745 0.005 3.664 655.131 1.268 0.638 high -0.158 
4 3.533 0.00037 4.264 715.301 1.563 0.621 high -0.576 
5 6.205 0.007 3.581 648.081 1.379 0.662 high 0.323 
6 3.596 0.014 3.797 624.053 1.020 0.646 high 0.022 
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Table 3. 
Compound 
MRDT hERG filter 
hERG 
pIC50 
AlkPhos GGT LDH SGOT SGPT 
                          expected values 
(>3.16 
mg/kg/dzień) 
(Yes/No) (>5.5) 
     
1 Below_3.16 Yes 6.74 NT NT NT NT NT 
2 Below_3.16 Yes 6.41 NT NT NT NT NT 
3 Below_3.16 Yes 7.07 NT NT NT NT NT 
4 Below_3.16 Yes 6.69 NT NT NT NT NT 
5 Below_3.16 Yes 6.20 NT NT NT NT NT 
6 Below_3.16 Yes 6.77 NT NT NT NT NT 
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Table 4. 
 1 2 3 4 5 6 
pKa UV-vis
a
 6.54 ± 0.01 6.94 ± 0.04 6.68 ± 0.05 7.09 ± 0.02 7.09 ± 0.02 6.90 ± 0.01 
HL
+
7.4 (%) 12 26 16 33 33 24 
L7.4 (%) 88 74 84 67 67 76 
max (nm) / (M
-1
cm
-1
) of HL
+
 288(5580) 
248(8150) 
290(9600) 
 
286(16925) 
244(21250) 
294(11640) 
250(14575) 
290(12760) 
254(15360) 
306(11090) 
244(13690) 
max (nm) / (M
-1
cm
-1
) of L
- 288(8965) 
284(16130) 
246(21140) 
292(9390) 
252(12075) 
290(11360) 
304(7650) 
246(1060) 
EM)max (nm) 445 445 443 439 445 452 
relative intensity
b
 0.004 0.124 0.128 0.095 0.329 1.000 
logK (HSA)
c
 5.8 ± 0.1 4.8 ± 0.1 n.d. 4.9 ± 0.1 < 4.8 5.8 ± 0.1 
KD
d
 1.6 M 16 M n.d. 13 M >16 M 1.6 M 
a
I = 0.1 M (KCl), values determined in aqueous phase; 
b
Relative fluorescence intensities measured at emission maxima at pH 7.4; 
 
c
Measured at pH 7.4 (20 mM phosphate buffer); 
d
KD = dissociation constants of the HSA adducts (KD = 1/ K). 
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Table 5. 
Compounds Gbind 
(kcal/mol) 
Gexp
a
 
(kcal/mol) 
r  
(Å) 
1 -7.04 -7.904 6.42 
       2.27 (-) 
2 -5.31 -6.541 7.58 
3 -3.03 -
* 
8.01 
4 -5.75 -6.678 6.04 
5 -4.09 < -6.541 5.81 
6 -8.26 -7.904 6.39 
       4.84 (-) 
                                a
 Gexp = -2.303·R·T·logK 
                     
*
overlapping quenching activity 
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